Novo Nordisk A/S (NVO)

Novo Nordisk traces back to 1923 when August Krogh, a Danish physiologist, won a Nobel Prize for work on capillary blood flow. His wife, Marie, licensed that discovery to Novo, a pharmaceutical startup. Novo merged with another Danish firm, Nordisk, in 1989, creating Novo Nordisk. The company has remained headquartered in Copenhagen and has accumulated a deep, durable presence in insulin and diabetes therapies — a market it essentially created in modern form.

The core business is insulin. Insulin is a hormone that regulates blood glucose. People with type 1 diabetes do not produce insulin; people with type 2 diabetes produce insulin but their bodies resist it. For nearly a century, insulin was extracted from pig and cow pancreases, a messy, expensive process that limited supply. In 1982, Genentech and Eli Lilly brought the first recombinant human insulin to market, made using genetically engineered bacteria. Novo Nordisk was not the first, but the company invested deeply in improving insulin formulations and delivery methods. The result was a portfolio of insulins — rapid-acting, long-acting, and mixed — that dominated global markets for decades.

Insulin remains a high-margin, recurring-revenue business. A person with type 1 diabetes or advanced type 2 diabetes must inject insulin every day for life. Novo Nordisk supplies insulins used by tens of millions of patients globally. The company also sells delivery devices — pens and pumps that make injecting insulin easier. That recurring demand is the foundation of the company’s economics.

But insulin alone is no longer a growth engine. The market is mature. Patents on older insulins have expired, and generic versions have eroded prices and margins. Novo Nordisk has responded by developing newer insulins (such as Tresiba, a long-acting insulin that requires less frequent injections) that offer clinical advantages and justify premium pricing. Yet growth in the insulin market itself is limited.

The company’s real growth story now centers on GLP-1 receptor agonists. GLP-1 is a hormone that regulates blood sugar and appetite. In the 1990s, researchers discovered that drugs mimicking GLP-1 could lower blood glucose and also cause weight loss. Novo Nordisk developed the first GLP-1 agonist, Victoza, approved in 2009 for type 2 diabetes. The company then developed a second-generation GLP-1, Ozempic, approved in 2012, which required just one injection per week instead of daily. Both were commercial successes in diabetes treatment. But the real inflection came when doctors and patients discovered that these drugs caused significant weight loss even in people without diabetes. Novo Nordisk repurposed a higher-dose version of Ozempic under the brand name Wegovy for obesity. Starting around 2020, Wegovy became a cultural phenomenon — celebrities used it, doctors prescribed it off-label, and demand exploded.

Obesity is a massive market. Hundreds of millions of people globally are overweight or obese, and there are almost no pharmacological options that actually work. Previous obesity drugs were either ineffective or had serious side effects. GLP-1 agonists are genuinely different — patients lose 15 to 20 percent of body weight. The addressable market is enormous compared to the diabetes market. Novo Nordisk launched Wegovy in the United States in 2021, and it rapidly became supply-constrained. Demand has remained so strong that Novo Nordisk has struggled to manufacture enough supply.

The obesity business is now transforming the company’s financials. Revenue and profit have surged. But this creates risk. First, supply constraints. Novo Nordisk has been investing heavily in manufacturing capacity, but ramping production of injectable drugs is capital-intensive and time-consuming. If competitors like Eli Lilly (which has developed its own GLP-1, Tirzepatide) satisfy demand before Novo Nordisk can increase supply, market share could shift. Second, sustainability of demand. It is unclear whether people taking Wegovy will stay on it forever or whether it is a fad. Some patients experience side effects (nausea, vomiting). Some stop taking it and regain weight. Novo Nordisk’s success assumes that a large, persistent installed base of patients will keep taking the drug for years. Third, competition. Eli Lilly’s Tirzepatide (Mounjaro, Zepbound) appears to be more effective at weight loss and is gaining share quickly. Other companies are developing GLP-1 agonists or rival mechanisms. The market could fragment, and Novo Nordisk might not retain pricing power.

Novo Nordisk also operates in women’s health and hormone therapies. The company makes growth hormone, hormone-replacement therapy drugs, and treatments for other hormone-related conditions. This segment is smaller than diabetes and obesity but stable and profitable.

From an operational standpoint, Novo Nordisk manufactures insulin and GLP-1 agonists in several countries, including Denmark, China, and the United States. The company has to source raw materials, manage complex manufacturing processes, and distribute to hospitals, pharmacies, and individual patients via patient-support programs. Regulatory approval is required in every market; the FDA, EMA, and other regulators set the bar for safety and efficacy. The company has a direct patient-support infrastructure in many countries, ensuring patients can get drugs and stay compliant with treatment.

Reimbursement is a pressure point. In the United States, insurance companies and pharmacy benefit managers (PBMs) negotiate prices. A major insurer might refuse to cover Ozempic unless the patient tries cheaper alternatives first, or might demand a rebate in exchange for broad coverage. In many other countries, government health systems set prices. Novo Nordisk has significant pricing power in GLP-1 agonists because alternatives are limited and the unmet need is so large, but that power is not unlimited.

The intellectual-property picture is mixed. Patents on first-generation GLP-1 agonists (like Victoza) have expired or are expiring, opening the door to generics. Patents on Ozempic and Wegovy are stronger but will eventually expire. The company must continuously develop next-generation products to maintain a moat.

Financially, Novo Nordisk is in a transition. Insulin revenue is stable but declining as a percentage of the total as GLP-1 obesity medicines grow. If obesity revenues grow as expected, overall profit should expand substantially, as the GLP-1 obesity market is vastly larger than the diabetes market. The stock price has surged based on this expectation. But the company is also investing heavily in manufacturing capacity to meet demand; that capital spending will depress free cash flow in the near term.

The Danish government and Novo Nordisk have negotiated over Wegovy pricing and supply. In Denmark and other Scandinavian countries, Novo Nordisk has agreed to lower prices in exchange for stable supply commitments and government support for manufacturing expansion. Those negotiations signal that governments view the obesity market as crucial to public health and are willing to broker deals.

Monitor the company’s quarterly earnings for updates on Wegovy demand, manufacturing capacity, and pricing developments. Watch for any announcements about capacity expansions or new manufacturing facilities. Track Eli Lilly’s Tirzepatide uptake and pricing — if Lilly gains share, it could pressure Novo Nordisk’s margins. Examine the pipeline for next-generation GLP-1 drugs or oral formulations (an oral GLP-1 would be more convenient than injection and could expand the addressable market further). Check the 10-K (SEC CIK 0000353278) for segment revenue breakdown and capital-spending plans. Finally, follow regulatory approvals for GLP-1 agonists in new indications — cardiovascular benefits, kidney disease, etc. — which could expand the patient population even beyond obesity and diabetes.